Purpose of this Study
We are doing this study to find out if an experimental drug called CTX131 (the study drug) is a safe and effective treatment for different forms of cancer with solid tumors. The study drug is made from white blood cells or T cells from healthy donors.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with clear cell renal carcinoma (ccRCC), cervical carcinoma (CC), esophageal carcinoma (EC), pancreatic adenocarcinoma (PAC), or malignant pleural mesothelioma (MPM)
- Have received at least one round of previous treatment
- Have never received treatment with anti-CD70 targeting agents
For more information about who can join this study, please contact the study team at 919-681-6468.
- Are diagnosed with clear cell renal carcinoma (ccRCC), cervical carcinoma (CC), esophageal carcinoma (EC), pancreatic adenocarcinoma (PAC), or malignant pleural mesothelioma (MPM)
- Have received at least one round of previous treatment
- Have never received treatment with anti-CD70 targeting agents
For more information about who can join this study, please contact the study team at 919-681-6468.
What is Involved?
If you choose to join this study, you will:
- Receive lympho-depleting chemotherapy
- Take the study drug
- Provide tumor tissue
- Have physical exams and blood draws
- Have imaging scans (CT and/or MRI)
- Have heart tests (ECG)
- Receive lympho-depleting chemotherapy
- Take the study drug
- Provide tumor tissue
- Have physical exams and blood draws
- Have imaging scans (CT and/or MRI)
- Have heart tests (ECG)
Study Details
Full Title
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX131) in Adult Subjects with Relapsed or Refractory Solid Tumors
Principal Investigator
Christopher
Hoimes
Protocol Number
PRO00112460
NCT ID
NCT05795595
Phase
I/II
Enrollment Status
OPEN TO ACCRUAL